Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

Phathom Pharmaceuticals announced its participation in Digestive Disease Week 2026, where it will present clinical and real-world data on VOQUEZNA (vonoprazan), a first-in-class potassium-competitive acid blocker for GERD treatment. The company reported Q1 2026 net revenues of $58.3 million, representing 104% year-over-year growth, with 1.35 million total VOQUEZNA prescriptions filled to date.

05/01/2026, 8:00 AM • GlobeNewswire

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.

04/13/2026, 1:00 PM • GlobeNewswire

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)

U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose on better-than-expected earnings.

01/08/2026, 8:41 AM • Benzinga

Stock Market Today: S&P 500, Dow Jones Futures Decline — AZZ, Northrop Grumman, Immuneering In Focus

U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose on better-than-expected earnings.

01/08/2026, 5:17 AM • Benzinga

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals priced a $130 million underwritten public offering consisting of 6.875 million shares of common stock at $16.00 per share and 1.25 million pre-funded warrants at $15.999 per warrant. The offering is expected to close on January 9, 2026, with net proceeds intended for general corporate purposes including working capital, commercialization, and R&D expenses. Guggenheim Securities and Cantor are serving as joint bookrunning managers.

01/07/2026, 10:33 PM • GlobeNewswire

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Phathom Pharmaceuticals will participate in the American College of Gastroenterology's 2025 Annual Scientific Meeting, showcasing VOQUEZNA® (vonoprazan) as an approved treatment for Gastroesophageal Reflux Disease (GERD) through product theater presentations and exhibit booth interactions.

10/23/2025, 8:00 AM • GlobeNewswire

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Phathom Pharmaceuticals will host a live webcast on October 30, 2025, at 8:00 am EDT to report its third quarter 2025 financial results and provide a business update, focusing on their gastrointestinal disease treatments.

10/20/2025, 8:00 AM • GlobeNewswire

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

Phathom Pharmaceuticals announced administrative changes to a Schedule 13D filing by Frazier Life Sciences, emphasizing that these changes do not represent a reduction in ownership position, but rather reflect reporting approach modifications.

08/20/2025, 8:00 AM • GlobeNewswire

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Phathom Pharmaceuticals will host a live webcast on August 7, 2025, at 8:00 am EDT to report its Q2 2025 financial results and provide a business update, focusing on their gastrointestinal disease treatments.

07/28/2025, 8:00 AM • GlobeNewswire